Extension Study of Talampanel for Amyotrophic Lateral Sclerosis
Study Title
- Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)
Teva Identifier
- ALS-TAL-201-OL
ClinicalTrials.gov Identifier
- NCT00982150
Study Status
- Terminated
Trial Condition(s)
- Amyotrophic Lateral Sclerosis
Interventions
- Drug: Talampanel
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 80 Years
Trial Duration
- 09/01/2009 - 06/01/2010
Phase
- Phase 2
Study Type
Interventional
